Overview

A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

Status:
Completed

Trial end date:
2014-02-03

Target enrollment:

Participant gender:

Summary

This study evaluates how once daily enzalutamide affects the metabolism of caffeine and dextromethorphan in men with prostate cancer by measuring concentrations of these drugs and their metabolites in plasma.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Collaborator:

Medivation, Inc.

Treatments:

Caffeine
Dextromethorphan